One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Background Lithium is widely evidenced for its neuropsychiatric benefits. Advantages of 'sub-
therapeutic'doses are increasingly being reported, which is apposite given enduring …

Background Intravenous racemic ketamine is a promising treatment for treatment-resistant
depression. However, its clinical utility compared with intranasal esketamine and the other …

Major depressive disorder is a highly prevalent psychiatric disorder. Despite an extensive
range of treatment options, about a third of patients still struggle to respond to available …

Background Antipsychotics (AP) have been used to augment antidepressant (AD)
medication in treatment‐resistant depression. In this study we examined factors (including …

Background Despite numerous national depression care guidelines (DCGs), suboptimal
antidepressant treatment may occur. We examined DCG concordance and depression …

There is a growing literature exploring the placebo response within specific mental
disorders, but no overarching quantitative synthesis of this research has analyzed evidence …

Major depressive disorder (MDD) is an often chronic and/or recurrent disorder that is
associated with dysfunctions in multiple aspects of life including work and non-workrelated …

Introduction A new era of treatment for adults with treatment-resistant depression (TRD),
which involves psychedelic substances, is dawning. Emerging evidence indicates that …